118.20
Novartis Ag Adr (NVS) 最新ニュース
Neuroendocrine Prostate Cancer Market Forecast Shows Accelerated CAGR Due to Diagnostic Advancements and Research Investment | DelveInsight - GlobeNewswire Inc.
What’s Next for Pharma Stocks After Trump’s Drug Price Ultimatum? - Morningstar
Sustainable dividends from European stocks poised to benefit from the tariff wars - The Globe and Mail
NVS’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Novartis Holds a Strong Branded Drug Portfolio, Supporting Steady Long-Term Growth - Morningstar
Novartis Beats On Q2 Earnings And Sales, CFO Retires, Stock Down - Barchart.com
Novartis ADR earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
Novartis Earnings: Double-Digit Sales Growth Supports Another Upgrade to Full-Year Guidance - Morningstar
Will Key Drugs Maintain Momentum For Novartis In Q2 Earnings? - Barchart.com
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement on Cosentyx® for hidradenitis suppurativa (HS) - Barchart.com
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study - TradingView
Incyte Gains 9.2% In Three Months: Buy, Hold Or Sell The Stock? - Barchart.com
5 Large Drug Stocks That Are Poised To Ride On Sector Recovery - Barchart.com
NVO Stock Gains After Parvus Asset Management Builds Stake - Barchart.com
The Novartis Oncology Young Canadian Investigator Awards (NOYCIA) returns for its 22nd year at ASCO 2025 - Barchart.com
Bristol Myers Collaborates With BNTX For Oncology Candidate - Barchart.com
Penicillin Market Research Report 2025 - GlobeNewswire Inc.
Why Value Investing Has Worked Better Outside the US - Morningstar
Which Industries are shaken when Trump's tariff stick swings towards the EU? - 富途牛牛
Regeneron Initial Data On Multiple Myeloma Drug Encouraging - Barchart.com
Bybit Gold & FX now supports stock trading: Explore new markets! - Bybit Announcement
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug - Yahoo Finance
Novartis Canada extends Health Equity Initiative effort, fueling innovation and impact for second year - Barchart.com
NVS’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Novartis Earnings: Strong First-Quarter Supports Increased Full-Year Guidance - Morningstar
Novartis ADR earnings beat by $0.20, revenue topped estimates - Investing.com
Novartis Holds a Strong Branded Drug Portfolio Supporting Steady Long-Term Growth - Morningstar
Novartis Beats On Q1 Earnings And Sales, Raises Guidance, Stock Up - Barchart.com
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up - Zacks Investment Research
Roche to invest US$50-billion in U.S. to avoid Trump tariffs, create 12,000 jobs - The Globe and Mail
大文字化:
|
ボリューム (24 時間):